Mumbai, December 30 (Udaipur Kiran): Shares of Lupin Limited traded marginally higher on Monday after the company announced a strategic licensing agreement with China-based Gan & Lee Pharmaceuticals for a novel GLP-1 receptor agonist. The stock was trading at ₹2,082.90, up by ₹3.40 or 0.16 per cent on the BSE.
The scrip opened at ₹2,098.95 and touched an intraday high of ₹2,099.60 and a low of ₹2,081.00. A total of 5,089 shares were traded during the session. The stock has a 52-week high of ₹2,403.45, recorded on January 2, 2025, and a 52-week low of ₹1,774.00, hit on April 7, 2025. The company’s current market capitalisation stands at ₹95,267.67 crore.
Promoters hold a 46.90 per cent stake in the company, while institutional and non-institutional investors hold 47.06 per cent and 6.06 per cent respectively.
Lupin has entered into an exclusive licensing, supply and distribution agreement with Gan & Lee Pharmaceuticals for a novel GLP-1 receptor agonist, Bofanglutide. The agreement strengthens Lupin’s diabetes portfolio and enhances its presence in the fast-growing obesity treatment segment.
Bofanglutide is a long-acting, once-in-two-weeks injectable therapy developed for the treatment of type 2 diabetes and weight management in overweight and obese patients. Clinical data suggest that the drug offers weight-loss outcomes comparable to or better than existing GLP-1 therapies, while providing the added benefit of less frequent dosing.
Under the agreement, Lupin will have exclusive rights to commercialise and distribute Bofanglutide in India, further strengthening its position in the specialty and chronic care segments.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.